Endothelial cell cytoskeleton (tumor vasculature context)

The **endothelial cell cytoskeleton** in tumor vasculature refers to the network of structural proteins and regulatory molecules (primarily actin filaments, microtubules, and associated effectors such as Rho GTPases and ROCK) that control endothelial cell shape, motility, adhesion, and permeability. In tumors, endothelial cytoskeletal structure and signaling are often abnormal, leading to defective vessel architecture, elevated permeability, and resistance to therapy; these features contribute to tumor progression and can be exploited therapeutically. While not a conventional drug target, molecular pathways that regulate the tumor endothelial cytoskeleton (e.g., Rho/ROCK, actin, microtubules) have become targets for anticancer drug development, both for direct antivascular therapy and to modulate the tumor microenvironment. Note: If you seek information on a *specific molecular entity* within the tumor endothelial cell cytoskeleton (e.g., RhoA, ROCK, β-actin, VE-cadherin), please specify that target. The current name is too broad and functionally descriptive to map to a single canonical molecule or receptor.

Other names

Tumor endothelial cytoskeletonTumor endothelial actin cytoskeletonTumor vascular cytoskeleton

Microtubule stabilization (e.g., taxanes prevent disassembly) Actin cytoskeleton disruption (e.g., combretastatin A-4 phosphate triggers cytoskeletal reorganization/blebbing) Inhibition of contractility or tension (e.g., ROCK inhibitors impede Rho-mediated actomyosin contractility) Modulation of cytoskeletal dynamics and vascular permeability/normalization